ABSTRACT
Diagnosis and classification of myelodysplastic syndromes (MDS) have traditionally been based on histopathologic and clinical features consisting of cytopenias, dysplastic morphologic features, abnormal marrow cellularity, an increased proportion of blast cells, and clonal karyotypic abnormalities (see chaps. 1 and 9). The combination of obvious marrow dysplasia and clonal karyotypic abnormalities is considered diagnostic for MDS, with each technology confirming the other.
